REC-2615

REC-2615 is a small molecule research compound that acts as a selective alpha-1B adrenergic receptor antagonist. It exhibits high affinity and selectivity for the alpha-1B subtype over alpha-1A and alpha-1D receptors, with Ki values of 0.3 nM, 1.9 nM, and 2.6 nM, respectively. Developed through research efforts involving Recordati and SmithKline Beecham (now GSK), the compound has been utilized in preclinical studies to investigate the role of adrenergic signaling in female sexual dysfunction, specifically focusing on its ability to modulate vaginal smooth muscle contractility and genital engorgement. Animal studies have also demonstrated its ability to decrease diastolic blood pressure and increase intracavernous pressure. Despite its pharmacological potency and selectivity, REC-2615 is primarily recognized as a pharmacological tool for receptor characterization rather than a candidate in an active pharmaceutical development program.

Other names

1-[4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-[2-methoxy-6-(1-methylethyl)phenoxy]-ethanone